BRISK SALES OF FLAGSHIP BIOSIMILARS Seo reiterated that the Korean biosimilar giant is on course to meet the sales target of 5 trillion won ($3.9 billion) for 2025 thanks to the brisk sales of its flagship copycat drugs, especially Remsima, the world’s first biosimilar to Janssen’s Remicade, a treatment for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and severe or disabling plaque psoriasis in adults.“We have sold more than 1 trillion won worth of Remsima so far this year, and its sales are expected to exceed 1 trillion won again next year,” said Seo.“We are on course to meet our 5 trillion won sales target for next year.” He projected 730 billion won in sales of Remsima SC, the world's first subcutaneous formulation of biosimilar infliximab developed by Celltrion, in 2025.
The biosimilar giant also plans to operate research and development centers in India, the US and Europe for its CDMO business, according to the company’s CDMO business strategy unveiled by the chairman at its investment roadshow held in Hong Kong on Wednesday.“We need approximately 500 researchers who are doctoral degree holders to expand our CDMO business but our R&D human resources fall short of that,” said Seo.“We will open new R&D centers with more staff and plan to conduct research requiring repetitive tasks in India.”Seo expected Celltrion would start generating revenue from CDMO operations in 2028.
South Korea’s leading biosimilar developer Celltrion Inc.will break ground on its first contract development and manufacturing organization (CDMO) plant in Korea next year, its chairman said about three months after the company unveiled a plan to venture into the CDMO market.
The story "Celltrion to break ground on CDMO plant in 2025: Chairman Seo" has 558 words across 20 sentences, which will take approximately 3 - 5 minutes for the average person to read.
Which news outlet covered this story?
The story "Celltrion to break ground on CDMO plant in 2025: Chairman Seo" was covered 7 hours ago by Korea Economic Daily, a news publisher based in South Korea.
How trustworthy is 'Korea Economic Daily' news outlet?
Korea Economic Daily is a fully independent (privately-owned) news outlet established in 1964 that covers mostly economy news.
The outlet is headquartered in South Korea and publishes an average of 10 news stories per day.
It's most recent story was published 45 minutes ago.
What do people currently think of this news story?
The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.
How do I report this news for inaccuracy?
You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
